[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 347
Citations 0
Editorial
October 2016

New Reasons to Pursue the Therapeutic Potential of Synthetic Nucleic Acids for Neurological Diseases

Author Affiliations
  • 1Department of Biochemistry and Molecular Genetics, UAB Stem Cell Institute, University of Alabama at Birmingham
  • 2Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
JAMA Neurol. 2016;73(10):1175-1177. doi:10.1001/jamaneurol.2016.2571

The use of short, synthetic nucleic acids as potential therapeutics was proposed more than 3 decades ago. However, improvements in the design and synthesis of nucleic acids have recently piqued the interest of researchers and physicians searching for alternative approaches for treating diseases that do not conform to traditional drug discovery programs. The advent of novel modified nucleic acids with better efficacy, stability, and cell penetrance combined with advancements in various delivery systems and methods, including intrathecal administration to allow direct entry to the central nervous system, provide sufficient rationale to cultivate the therapeutic capabilities of synthetic nucleic acids for neurological diseases.

First Page Preview View Large
First page PDF preview
First page PDF preview
×